Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2008 June 2; 118(6): 2018–2021.
Published online 2008 May 22. doi:  10.1172/JCI35931
PMCID: PMC2391280

A signaling pathway AKTing up in schizophrenia


The serine/threonine protein kinase AKT (also known as PKB) signaling pathway has been associated with several human diseases, including schizophrenia. Studies in preclinical models have demonstrated that impaired AKT signaling affects neuronal connectivity and neuromodulation and have identified AKT as a key signaling intermediary downstream of dopamine (DA) receptor 2 (DRD2), the best-established target of antipsychotic drugs. A study by Tan et al. in this issue of the JCI strengthens links among AKT signaling, DA transmission, and cognition in healthy individuals and offers potential avenues to explore in an effort to find more effective pharmacotherapies for schizophrenia and related disorders (see the related article beginning on page 2200).

AKT (also known as PKB) is a key mediator of signal transduction processes mediated by protein phosphorylation and dephosphorylation (1) and a central node in cell signaling downstream of growth factors, cytokines, and other external stimuli. The AKT gene family includes three members (AKT1, AKT2, AKT3), which possess partially redundant functions and contribute to several cellular functions including cell growth, survival, and metabolism. AKT has several substrates, most notable among them glycogen synthase kinase 3α (GSK-3α) and GSK-3β, both of which are inhibited by AKT in response to various external cellular stimuli (1).

AKT signaling and susceptibility to schizophrenia

Gain or loss of AKT activity has been associated with several human diseases, including cancer and type 2 diabetes (1). Since the initial report in 2004 from Emamian et al. (2), accumulating evidence suggests that impaired AKT signaling also plays a role in the pathogenesis of schizophrenia. First, an association between schizophrenia and AKT1 genetic variants (Figure (Figure1A)1A) has been reported in several case/control samples and family cohorts (an updated compilation of such studies is now available; see ref. 3). Second, a number of studies have provided convergent evidence of a decrease in AKT1 mRNA, protein, and activity levels (reflected by changes in substrate phosphorylation) in brains of some individuals with schizophrenia (2, 4, 5). Negative findings have also been reported in some patient cohorts (3), but overall, an increasingly strong link between a dysregulation of AKT signaling and schizophrenia is emerging. Importantly, pharmacological evidence indicates that drugs used in the management of psychosis, such as the typical antipsychotic haloperidol as well as several atypical antipsychotics, can act as enhancers of AKT signaling in vivo or in vitro by directly activating AKT or by increasing the phosphorylation of its substrates GSK-3α and GSK-3β (reviewed in ref. 6).

Figure 1
AKT1 genetic variation and its impact on multiple levels of neuronal function.

AKT signaling and dopamine transmission

In elucidating the molecular basis of the link between AKT signaling and schizophrenia, one of the first clues came from the observation that mice lacking the Akt1 gene show enhanced sensitivity to disruption of sensory motor gating by amphetamine (2). One action of this drug is to cause the release of dopamine (DA) at nerve terminals and thus increase DA transmission via G protein–coupled DA receptors. The two major classes of DA receptors, the DA receptor 1 (DRD1) class and the DA receptor 2 (DRD2) class, signal through increases and decreases, respectively, in cAMP levels within nerve cells. Sensitivity to amphetamine is widely used to model psychosis in rodents and is efficiently prevented by blocking DRD2, the best-established target of antipsychotic drugs (69). Moreover, Akt1-knockout mice show a more pronounced deficit in response to DRD2 class but not DRD1 class agonists in working memory tests that depend on proper function of prefrontal cortex (PFC) (10). In a series of elegant experiments, Caron and colleagues have established that AKT is a novel and key signaling intermediary downstream of DRD2 class receptors (6, 8, 11). These experiments demonstrate that DRD2 class receptors are essential for the inhibition of AKT by DA and that AKT function is important for normal dopaminergic transmission and expression of DA-associated behaviors in a manner distinct from cAMP-dependent signaling. Thus, a hypothesis has been formulated according to which a partial loss of function of AKT1 in schizophrenia, mimicking DA overactivity, results in exacerbated responses to DRD2 class receptor stimulation (Figure (Figure1B).1B). Antipsychotics acting by blocking DRD2 class receptors could correct this imbalance by preventing further reductions of AKT activity by these receptors (10, 11).

AKT signaling and neuronal connectivity

AKT signaling has also been implicated in the downstream cellular effects of GABA and glutamate released at nerve terminals (12, 13). In addition, AKT signaling is known to modulate the development of neuronal connectivity in vitro (14) as well as in the human brain (15). Notably, Akt1-deficient mice show changes in neuronal connectivity of PFC layer V neurons (10), the output neurons of the cortex. Transcriptional profiling in the PFCs of these mice identified concerted changes in genes controlling synaptic function, neuronal development, myelination, and actin polymerization. Thus, impaired AKT and, in particular, AKT1 signaling may have an additive effect on the properties of neural networks, resulting in neuronal disconnectivity as well as aberrant neuromodulation. How these effects interact at the circuit level and neural systems levels to modulate the input/output function of specific brain areas is the focus of active investigation.

From neurons to neural systems and cognition

Along these lines, in the current issue of the JCI, Tan and colleagues report on their investigations of whether genetic variation in the AKT1 gene influences structural and functional measures sensitive to changes in cortical DA signaling (16). This approach investigated discrete and diagnostically independent disease components rather than clinical entities. The authors started with 5 AKT1 SNPs previously associated with schizophrenia and investigated in healthy human subjects which of these markers was associated with a cognitive test battery designed to measure a wide range of cognitive processes such as attention, memory, language comprehension, and processing speed. They found the strongest associations with the A allele of the AKT1 SNP rs1130233 (Figure (Figure1A)1A) and certain indices of frontal lobe function, such as IQ and executive function. In line with animal research implicating reduced AKT function in cognitive deficits (10), the A allele of rs1130233 was also associated with reduced AKT1 expression in B lymphoblasts of healthy individuals. Examining AKT1 expression in these peripheral cells offers a compromise because it is not possible to directly assess the impact of genetic variants in live human brain tissue. These observations thus provide a possible link between reduced AKT1 function and cognition in humans.

In order to examine more closely how AKT may influence cognition, the authors administered an explicit task of working memory and executive function, the N-back task, which measures the ability to remember and manipulate information in short-term memory. Healthy human subjects who varied in their genotypes at the AKT1 locus completed the N-back task while undergoing functional MRI (16). Importantly, optimal execution of this task critically depends on proper levels of DA within the PFC: either too much or too little DA can impair performance (17). Interestingly, those individuals who carried the AKT1 rs1130233 A allele had relatively inefficient information processing in the PFC. Thus, in order to achieve the same level of performance, these volunteers required increased activation of their PFCs. This may result from the impact of AKT on DA function, its role in establishing cortical connections, or both. To begin addressing this question, the authors also examined a functional polymorphism (Val158Met) of the catechol-O-methyltransferase (COMT) gene, which is responsible for breaking down DA, particularly within the PFC; the presence of the Val158 allele leads to lower DA levels. Previous work in preclinical models has shown that variation in the activity of this gene can modulate the effects that other schizophrenia susceptibility loci have on cortical DA transmission and related behaviors (18). Tan et al. (16) found that carriers of the AKT1 rs1130233 A allele and two COMT Val158 alleles had disproportionately inefficient prefrontal cortical processing, suggesting perhaps a genetic interaction between these two DA-related genes. Interestingly, they also found AKT1 rs1130233 A allele carriers had reduced gray matter volumes of the caudate nucleus of the basal ganglia and the right PFC, with the latter again disproportionately reduced in those individuals also carrying two COMT Val158 alleles. These results may indicate how genetic variation of AKT1 may increase risk for psychiatric disorders, such as schizophrenia, which is linked to DA and PFC dysfunction. Indeed, the authors provide further evidence for association of the AKT1 rs1130233 A allele and the diagnosis of schizophrenia.

Unresolved questions and therapeutic prospects

Several questions remain, however, as to exactly how impaired AKT signaling leads to impaired cognition. There is a clear link between DA and AKT signaling (11), and the current study links AKT-dependent DA signaling with working memory in humans (16). However, AKT requires a timescale of minutes to achieve its effects on DRD2 signaling, whereas working memory operates on a timescale of seconds (11). It is interesting that the basal ganglia play a critical role in regulating information flow within working memory networks (19), but this gating is also rapid, much faster than the immediate influence of AKT on DRD2 signaling in either the caudate or PFC. It is possible, however, that long-term AKT deficiency reorganizes cortical and even perhaps basal ganglia networks and their functional modulation by DA. Indeed, DRD2 sensitization resulting from reduced AKT function coupled with decreased cortical DRD1 signaling resulting from increased COMT activity may alter the DRD1/DRD2 activation ratio and affect how information is processed in the PFC (Figure (Figure1C)1C) (17). This may ultimately contribute to cognitive deficits and predisposition to schizophrenia.

The observation that both typical and atypical antipsychotics can compensate for impaired AKT signaling in schizophrenia coupled with the more recent observation that lithium (a pharmacological agent used for the management of bipolar disorder, schizophrenia, and depression) also directly regulates AKT signaling (7) suggest that this pathway may be a prime target for the design of effective targeted therapies for patients with specific genetic predisposition to schizophrenia or related disorders. However, it also highlights concerns regarding current schizophrenia pharmacotherapies, which primarily target DRD2 class receptors yet are inadequate in improving cognition (20) and produce serious side effects. At this point, it remains unclear how therapies that target AKT signaling will benefit the schizophrenia-associated cognitive measures linked to this pathway (16). On the other hand, the gene expression changes associated with AKT1 risk variants are low and the development of serious side effects due to the multifunctionality of the AKT pathway may be avoided if directed therapies only need to provide relatively modest functional enhancement in order to reach an effective threshold. Moreover, because the AKT1 risk variants are common, a low disease risk corresponds to a large population attributable risk (if the population were monomorphic for the nonrisk allele, the prevalence of the disease would be considerably lower). Therefore, AKT signaling pathway–directed therapies may be beneficial to a large group of patients.


Nonstandard abbreviations used: COMT, catechol-O-methyltransferase; DA, dopamine; DRD2, dopamine receptor 2; GSK-3α, glycogen synthase kinase 3α; PFC, prefrontal cortex.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 118:2018–2021 (2008). doi:10.1172/JCI35931.

See the related article beginning on page 2200.


1. Woodgett J.R. Recent advances in the protein kinase B signaling pathway. Curr. Opin. Cell Biol. 2005;17:150–157. doi: 10.1016/ [PubMed] [Cross Ref]
2. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004;36:131–137. doi: 10.1038/ng1296. [PubMed] [Cross Ref]
3. Schizophrenia Research Forum. 2008. Gene overview of all published schizophrenia-association studies for AKT1. .
4. Thiselton D.L., et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol. Psychiatry. 2008;63:449–457. doi: 10.1016/j.biopsych.2007.06.005. [PMC free article] [PubMed] [Cross Ref]
5. Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr. Res. 2006;84:1–14. doi: 10.1016/j.schres.2006.02.009. [PubMed] [Cross Ref]
6. Beaulieu J.M., et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. . J. Neurosci. 2007;27:881–885. doi: 10.1523/JNEUROSCI.5074-06.2007. [PubMed] [Cross Ref]
7. Beaulieu J.M., et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008;132:125–136. doi: 10.1016/j.cell.2007.11.041. [PubMed] [Cross Ref]
8. Beaulieu J.M., et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122:261–273. doi: 10.1016/j.cell.2005.05.012. [PubMed] [Cross Ref]
9. Beaulieu J.M., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U. S. A. 2004;101:5099–5104. doi: 10.1073/pnas.0307921101. [PubMed] [Cross Ref]
10. Lai W.S., et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl. Acad. Sci. U. S. A. 2006;103:16906–16911. doi: 10.1073/pnas.0604994103. [PubMed] [Cross Ref]
11. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007;28:166–172. doi: 10.1016/ [PubMed] [Cross Ref]
12. Wang Q., et al. Control of synaptic strength, a novel function of Akt. Neuron. 2003;38:915–928. doi: 10.1016/S0896-6273(03)00356-8. [PubMed] [Cross Ref]
13. Qin Y., et al. State-dependent Ras signaling and AMPA receptor trafficking. Genes Dev. 2005;19:2000–2015. doi: 10.1101/gad.342205. [PubMed] [Cross Ref]
14. Jaworski J., et al. Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway. J. Neurosci. 2005;25:11300–11312. doi: 10.1523/JNEUROSCI.2270-05.2005. [PubMed] [Cross Ref]
15. Boland E., et al. Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. Am. J. Hum. Genet. 2007;81:292–303. doi: 10.1086/519999. [PubMed] [Cross Ref]
16. Tan H.-Y., et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. . J. Clin. Invest. . 2008;118:2200–2208. [PMC free article] [PubMed]
17. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27:683–690. doi: 10.1016/j.tins.2004.08.002. [PubMed] [Cross Ref]
18. Paterlini M., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat. Neurosci. 2005;8:1586–1594. doi: 10.1038/nn1562. [PubMed] [Cross Ref]
19. McNab F., Klingberg T. Prefrontal cortex and basal ganglia control access to working memory. Nat. Neurosci. 2008;11:103–107. doi: 10.1038/nn2024. [PubMed] [Cross Ref]
20. Green M.F. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am. J. Psychiatry. 2007;164:992–994. doi: 10.1176/appi.ajp.164.7.992. [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation